Williams Jones Wealth Management LLC. Buys 1,611 Shares of Eli Lilly and Company (NYSE:LLY)

Williams Jones Wealth Management LLC. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,693 shares of the company's stock after acquiring an additional 1,611 shares during the quarter. Williams Jones Wealth Management LLC.'s holdings in Eli Lilly and Company were worth $22,151,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in LLY. Victrix Investment Advisors purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $936,000. Vident Advisory LLC grew its position in Eli Lilly and Company by 16.0% in the 4th quarter. Vident Advisory LLC now owns 32,617 shares of the company's stock worth $25,182,000 after purchasing an additional 4,500 shares in the last quarter. Vienna Asset Management LLC purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $1,254,000. Virtus Investment Advisers Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $154,000. Finally, Visionary Wealth Advisors lifted its position in shares of Eli Lilly and Company by 28.0% during the 4th quarter. Visionary Wealth Advisors now owns 2,153 shares of the company's stock worth $1,662,000 after buying an additional 471 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Citigroup cut their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Down 1.4%

Eli Lilly and Company stock traded down $10.11 during trading hours on Thursday, reaching $714.84. The stock had a trading volume of 4,242,720 shares, compared to its average volume of 3,609,166. The company has a fifty day simple moving average of $793.65 and a 200-day simple moving average of $804.27. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The stock has a market cap of $677.48 billion, a PE ratio of 61.05, a PEG ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the business earned $2.58 EPS. The business's revenue was up 45.2% compared to the same quarter last year. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.84%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.